Tara L. Spires‐Jones

This study examines how DNAm PhenoAge, a biomarker of biological ageing, relates to health outcomes and cognitive ability across the lifespan, finding that early-life cognitive factors influence later-life health.

This study shows that reducing tau improves behavioural and transcriptional issues in a mouse model of Alzheimer’s disease, suggesting synaptic tau reduction could be a therapeutic strategy.

The paper shows that Aβ oligomers from AD brain bind to synapses and disrupt synaptic activity, and this requires APP.